Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 14:9:218.
doi: 10.3389/fgene.2018.00218. eCollection 2018.

Associations Between XPD Lys751Gln Polymorphism and Leukemia: A Meta-Analysis

Min Wen  1   2   3 , Bo Zhou  2 , Xin Lin  2 , Yunhua Chen  2 , Jialei Song  1   3 , Yanmei Li  1   3 , Eldad Zacksenhaus  4 , Yaacov Ben-David  1   3 , Xiaojiang Hao  1   3
Affiliations

Associations Between XPD Lys751Gln Polymorphism and Leukemia: A Meta-Analysis

Min Wen et al. Front Genet. .

Abstract

Objectives: The aim of the present study was to define the potential relationship between xeroderma pigmentosum group D (XPD) Lys751Gln polymorphisms and the risk of leukemia. Methods: A comprehensive search of Pubmed, Web of Science, EBSCO, the Cochrane Library and China National Knowledge Infrastructure was conducted to identify original articles published before March 2017 concerning the association between XPD Lys751Gln polymorphisms and leukemia risk. A literature quality assessment was performed using the Newcastle-Ottawa Scale. Heterogeneity across studies was assessed using I2 statistics. Random- or fixed-effects models were used to calculate pooled odds ratios (ORs) in the presence or absence of heterogeneity, respectively. Sensitivity analysis was used to assess the influence of individual studies on the pooled estimate. Publication bias was investigated using funnel plots and Egger's regression test. All data analyses were performed using Stata 14.0 and Revman 5.3. Results: Fourteen studies with a total of 7525 participants (2,757 patients; 4,768 controls) were included in this meta-analysis. We found that XPD Lys751Gln polymorphisms significantly increased the risk of developing leukemia in both dominant OR = 1.21, 95%CI [1.10-1.35], P ≤ 0.001) and heterozygote (OR = 1.22, 95%CI [1.09-1.36], P ≤ 0.001) model. An allele model showed a borderline significant increase in leukemia risk (OR = 1.13, 95%CI [1.00-1.27], P = 0.05). A subgroup analysis revealed a consistent association between XPD Lys751Gln polymorphisms and leukemia risk for some genetic models in Caucasian populations, adult or chronic groups, and in almost all models of childhood or acute groups. Conclusion: Our results indicate that XPD Lys751Gln polymorphism increases the risk of leukemia, especially in childhood and acute cases.

Keywords: ERCC2; XPD; leukemia; meta-analysis; polymorphism.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
A flow diagram showing the study selection process for the meta-analysis.
FIGURE 2
FIGURE 2
Comparison of XPD Lys751Gln for overall data in dominant model (Gln/Gln + Lys/Gln vs. Lys/Lys). (A) Forest plot, (B) funnel plot, (C) sensitivity analysis.
FIGURE 3
FIGURE 3
Comparison of XPD Lys751Gln for overall data in heterozygote model (Lys/Gln vs. Lys/Lys). (A) Forest plot, (B) funnel plot, (C) sensitivity analysis.
FIGURE 4
FIGURE 4
Comparison of XPD Lys751Gln for overall data in recessive model (Gln/Gln vs. Lys/Gln + Lys/Lys). (A) Forest plot, (B) funnel plot, (C) sensitivity analysis.
FIGURE 5
FIGURE 5
Comparison of XPD Lys751Gln for overall data in homozygote model (Gln/Gln vs. Lys/Lys). (A) Forest plot, (B) funnel plot, (C) sensitivity analysis.
FIGURE 6
FIGURE 6
Comparison of XPD Lys751Gln for overall data in allele model (Gln vs. Lys). (A) Forest plot, (B) funnel plot, (C) sensitivity analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Allan J. M., Smith A. G., Wheatley K., Hills R. K., Travis L. B., Hill D. A., et al. (2004). Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104 3872–3877. 10.1182/blood-2004-06-2161 - DOI - PubMed
    1. Arber D. A., Orazi A., Hasserjian R., Thiele J., Borowitz M. J., Le Beau M. M., et al. (2016). The revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 2391–2405. 10.1182/blood-2016-03-643544 - DOI - PubMed
    1. Banescu C., Iancu M., Trifa A. P., Dobreanu M., Moldovan V. G., Duicu C., et al. (2016). Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population. Tumour Biol. 37 9357–9366. 10.1007/s13277-016-4815-6 - DOI - PubMed
    1. Banescu C., Trifa A. P., Demian S., Benedek Lazar E., Dima D., Duicu C., et al. (2014). Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia. Biomed Res. Int. 2014:213790. 10.1155/2014/213790 - DOI - PMC - PubMed
    1. Batar B., Guven M., Baris S., Celkan T., Yildiz I. (2009). DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Leuk. Res. 33 759–763. 10.1016/j.leukres.2008.11.005 - DOI - PubMed